Our Objective:

Accelerated Therapeutics proposes to repurpose generic drugs for new indications based on novel pathogenesis discoveries. Repurposing can be protected by method of use patents, as was the case with Viagra. We already own US patents for 3 such opportunities.

Value Proposition:

The value proposition to patients and insurance companies is a superior treatment option, at a fraction of the cost of expensive proprietary drug regimens.

Clinical Development Advantage:

Repurposing can typically be started in a Phase II human proof of efficacy setting, as the drugs have already passed Phase I human safety trials. This results in a short time to market, at low risk and low cost, and is in stark contrast to the very expensive, high risk, and extremely long time to market required for new drug development.

Our Methodology:

Step 1: Our process starts with a Mechanism of Action (MOA) intensive approach of mapping out the molecular pathways underlying the etiology and pathology (pathogenesis) of a disease condition. Repurposing candidates are then identified on mechanistic ability to inhibit either the earliest pathways of the etiology or to inhibit the largest number of pathways in the pathogenesis.

Step 2: Human Clinical data is then reviewed for consistency with the novel pathogenesis and for support for the MOA selected to inhibit the pathogenesis. Academia published studies are avoided when possible because of their high unreliability rate (e.g. Amgen found 47 of the 53 landmark oncology studies published by academia were not reproducible). All studies that are inconsistent with known MOAs and pathways, or do not disclose the MOAs or pathways underlying the claimed empirical results, are largely ignored.

Step 3: The final step is evaluating if the proposed treatment can be expected to provide a therapeutically superior treatment option relative to the current best standard of care.

Three Already Identified Opportunities:

1) Growth Factor Receptor Modulated Cancer Protocols (U.S.: $ 17 Billion Available Market)
- for EGFR overexpressing cancers and estrogen-driven prostate cancer

2) Calcium Ion (Ca++) Homeostasis for Epilepsy and Migraines (U.S.: $ 7.5 Billion Market)
- a pathogenesis inhibiting approach for preventing Seizures and Migraines

3) Targeted Transient Ribosomal Inhibition (U.S.: $ 15 Billion Market)
- a platform drug for several pulmonary and dermal indications

Contact Info: Contact our Business Advisor Richard Lepidi, CFA if you have interest in any of the above therapeutic areas at lepidi1110@comcast.net, or 412.381.3360

© 2017 Mark J. Zamoyski